About
Ordaos develops AI-driven de novo designed mini-proteins and single domain antibodies to accelerate the creation of novel therapies for drug discovery, focusing on safer, more effective protein therapeutics that are easier to manufacture.
Explore Ordaos's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.